

## Appendix 4C





Oneview Healthcare plc

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C

Quarter Ended 31 March 2024

23 April 2024



*Oneview installation in Mercy's Love Family Women's Center in Oklahoma City went live on 7<sup>th</sup> April 2024*

**Baxter Partnership  
Progresses**



**2 New Logos Added**



**17,808  
Contracted Beds**




## ASX Release

### Appendix 4C – Q1 2024 Quarterly Cash Flow Report

23 April 2024 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 March 2024 (Q1 24).

#### Financial Highlights

The Company had a net operating cash outflow of €2.1m, an increase of 9% compared to the prior year corresponding quarter, due to higher staff costs as the Company resources the fulfilment of recent new signings and the Baxter pipeline.



Key components of the operating cash outflow in the quarter comprised:

- Receipts from customers totalled €2.6m. (A\$4.3m), an increase of 24% on the prior year corresponding period.
- Payments in respect of staff costs of €2.5m (A\$4.2m) were 8% higher than the prior quarter with the hiring of new staff to resource the recent new signings and the Baxter pipeline. €283k of the development costs of the MyStay Mobile product have been capitalised in line with IFRS criteria in the quarter.
- Admin and corporate costs of €874k (A\$1.5m) were slightly higher than the prior quarter due to the cessation of the free rent period associated with the less expensive rent for the smaller Dublin premises.

The Company held cash balances of €9.1m (A\$15.1m) as at 31 March 2024, with zero debt.


The Company received formal notification from the Irish Revenue Commissioners to expect payment of €925,000 in research and development tax credits with respect to financial years 2020 through 2022. The Company expects to receive these claim proceeds in April 2024. The Company also agreed a Phased Payment Arrangement for its €2.48m Covid related warehoused payroll tax liabilities, which will result in a repayment of an initial 10% "down payment" in April 2024 and the remaining balance being repaid in 60 equal instalments over a 5-year period with a 0% interest rate.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €313,000 (A\$520,000).

### **Operational Highlights**

- A Master Services Agreement was signed with Inova Health System (Inova) for 1,900 beds and an initial 5-year term. The first installation at Inova's Potomac Yard facility has commenced planning after the Statement of Work was signed last month.
- On 5 April 2024, the Company signed a Master Technology Agreement (MTA) with Mercy Health System (Mercy) for an initial 3-year term. Mercy, one of the 20 largest U.S. health systems, is a highly integrated, multi-state health care system across the seven states of Arkansas, Kansas, Louisiana, Mississippi, Missouri, Oklahoma and Texas. The MTA outlines the general terms and conditions governing Oneview's provision of software, professional services and support services to Mercy. The deployment for future hospitals will be governed by a separate ordering document in accordance with the terms set forth in the MTA. The initial 87 bed deployment of Oneview's Cloud Hosted Care Experience Platform (CXP) at Mercy's Love Family Women's Center in Oklahoma City went live on Sunday 7 April 2024. (The contract for this hospital was signed on 31 January 2024).
- The Baxter partnership is gathering momentum. Oneview received the first Purchase Order from Baxter for Nicklaus Children's Hospital in Florida, to deploy our Digital Door Sign. This is due to be installed by the end of H1.
- The partnership has resulted in a material increase in the sales pipeline, which has seen ~98% growth in qualified leads compared to March 2023.
- Baxter's Care Communication Executives are now receiving further sales training to support the selling of MyStay Mobile and the new iteration of our Digital Door Sign.
- It should be noted that the Mercy MTA and the Inova MSA signing mentioned above were contracted directly by Oneview and the initiation of both of these sales processes pre-date the signing of the Value Added Reseller Agreement with Baxter announced on 19 June 2023.
- There has been significant marketing activity in the quarter with the Company's attendance at VIVE and HIMSS. James Fitter, CEO of Oneview, participated in a podcast with Verizon's Robin Goldsmith entitled "Compassionate Technology". It can be accessed [HERE](#).
- The pilot of MyStay Mobile went live successfully on 13 Feb at a unit in NYU Langone Health's Long Island Community Hospital. The goal of the pilot was to refine the implementation approach, understand user engagement, and optimize the user onboarding funnel. Several optimizations have been identified and are currently in development.

- The MyStay Mobile product launched formally on 26 Feb. A MyStay Mobile Discussion Panel webinar took place in March and can be downloaded [HERE](#).
- Three product releases were delivered in the quarter:
  - 2024.R1: this release included device pairing enhancements, “offline mode”, which ensures continuity of entertainment services in the event of system interruption, enhancements to the Virtual Care API, and other improvements.
  - 2024.R2: this release included the second iteration of Oneview’s Digital Door Sign. The Digital Door Sign provides “at a glance” information relevant to patient care, at the door of the patient room. This release includes a new look and feel, interactivity with the ability to add “care flags”, as well as support for workflows related to infection risk.
  - MyStay Mobile Phase 2: this release included meal ordering and other improvements.



## Outlook

Oneview entered 2024 with three key growth drivers that are proving transformational for the Company:

1. Health systems' renewed focus on leveraging patient experience platforms to deliver inpatient virtual-care;
2. The launch of MyStay Mobile, which has expanded the addressable market by eliminating the need for in-room hardware; and
3. The Baxter partnership, which is providing the company unparalleled access to the US market.

The signing of Inova and Mercy demonstrate that the Company can deliver on this growth potential. These are the two prominent US healthcare systems that we stated that we were in late stage negotiations with in our last quarterly release.

Other sales opportunities are progressing well through the pipeline. We look forward to updating the market as contracts are signed. It should be noted that enterprise contracts in healthcare are complex and when we have been selected as vendor of choice, there is no guarantee that the issuing party will ultimately procure our solution if, for example, hospital budgets remain constrained or their IT priorities change.

## ESG

The Company is committed to its Environmental, Social and Governance principles and is pleased to report continued progress, as measured against the World Economic Forum universal ESG framework. Details can be found [HERE](#) on our website and will continue to be reported on a quarterly basis.

This announcement has been approved for release by the board of Oneview Healthcare plc.

## About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in over 70 hospitals.

Enquiries:

James Fitter, CEO

Helena D'Arcy, CFO

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oneview Healthcare PLC

**ABN**

610 611 768

**Quarter ended ("current quarter")**31<sup>st</sup> March 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter €'000</b>	<b>Year to date (3 months) €'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	2,591	2,591
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,111)	(1,111)
(c) advertising and marketing	(166)	(166)
(d) leased assets	-	-
(e) staff costs	(2,498)	(2,498)
(f) administration and corporate costs	(874)	(874)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	15	15
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	(17)	(17)
1.7 Government grants and tax incentives	-	-
1.8 Other (working capital movements)	(78)	(78)
<b>1.11 Net cash from / (used in) operating activities</b>	<b>(2,138)</b>	<b>(2,138)</b>

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(12)	(12)
	(d) investments	-	-
	(e) intellectual property	(283)	(283)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(295)</b>	<b>(295)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>



## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	11,542	11,542
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(2,138)	(2,138)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(295)	(295)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	7	7
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>9,116</b>	<b>9,116</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter €'000</b>	<b>Previous quarter €'000</b>
5.1	Bank balances	6,106	5,826
5.2	Call deposits	3,010	5,716
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>9,116</b>	<b>11,542</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter €'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	313
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end €'000</b>	<b>Amount drawn at quarter end €'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
<b>7.4 Total financing facilities</b>	-	-
<b>7.5 Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8. Estimated cash available for future operating activities</b>	<b>€'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,138)
8.2 Cash and cash equivalents at quarter end (item 4.6)	9,116
8.3 Unused finance facilities available at quarter end (item 7.5)	-
<b>8.4 Total available funding (item 8.2 + item 8.3)</b>	<b>9,116</b>
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	<b>4.26</b>
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....23 April 2024.....

Authorised by: ..... **BY THE BOARD**.....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.